The effect of pulmonary function testing on bleomycin dosing in germ cell tumours
| Autor: | Guy C. Toner, Howard Gurney, M. Rosenthal, Mark D. Chatfield, Peter Grimison, Baerin Houghton, Martin R. Stockler, Michael Friedlander, Felicia Roncolato, Damien Thomson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Vital capacity
Pulmonary toxicity business.industry respiratory system medicine.disease Bleomycin respiratory tract diseases Pulmonary function testing 03 medical and health sciences chemistry.chemical_compound FEV1/FVC ratio 0302 clinical medicine chemistry DLCO 030220 oncology & carcinogenesis Diffusing capacity Anesthesia Internal Medicine medicine 030212 general & internal medicine business Pneumonitis |
| Zdroj: | Internal Medicine Journal. 46:893-898 |
| ISSN: | 1444-0903 |
| Popis: | Background/AimThe utility of pulmonary function testing (PFT) to detect bleomycin-induced pneumonitis is controversial. We describe its impact on bleomycin dosing in a phase 2 trial of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours.MethodsThere were 12 planned weekly bleomycin doses for intermediate-risk and poor-risk disease and nine for good-risk disease. Clinical assessments, chest X-ray, diffusing capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) were performed bi-weekly. Bleomycin was ceased for predefined clinical/radiological evidence of pulmonary toxicity and a >25% reduction in DLCO or FVC. We determined doses planned, received and omitted and patients receiving all, two-thirds, two-thirds of planned bleomycin doses.ResultsOf 43 eligible patients, 30% had lung metastases. Of 471, 375 (80%) of planned bleomycin doses were received, and 30% received 25% reduction in DLCO (35 vs 24%, P=0.4) and 1.5 times as likely to receive |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text